A primer on the hormone-free interval for combined oral contraceptives

References

• Daniels K, Mosher WD. Contraceptive methods women have ever used: United States, 1982–2010. National Health Statistics Reports 2013;62:1-15. Available at: www.cdc.gov/nchs/data/nhsr/nhsr062.pdf [Last accessed August 2015]
   PubMedGoogle Scholar
• Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance, and benefits versus risks. Ther Adv Drug Saf 2014;5:201-13
   PubMedGoogle Scholar
• Black A, Francoeur D, Rowe T, et al. SOGC clinical practice guidelines: Canadian contraception consensus. J Obstet Gynaecol Canada 2004;26:219-96
   PubMedGoogle Scholar
• Baerwald AR, Pierson RA. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Canada 2004;26:19-24
   PubMedGoogle Scholar
• Davtyan C. Four generations of progestins in oral contraceptives. Proc UCLA Healthcare 2012;16:1-3
   Google Scholar
• Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case–control study. Contraception 2002;65:187-96
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343:d6423
   PubMed Web of Science ®Google Scholar
• de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014;3:CD010813
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance for Industry: Labeling for Combined Oral Contraceptives. 2004. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075075.pdf [Last accessed September 2014]
   Google Scholar
• Endrikat J, Gerlinger C, Richard S, et al. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception 2011;84:549-57
   PubMed Web of Science ®Google Scholar
• Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008;34:237-46
   PubMed Web of Science ®Google Scholar
• Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception 2011;84:19-34
   PubMed Web of Science ®Google Scholar
• Trussell J. Understanding contraceptive failure. Best Pract Res Clin Obstet Gynaecol 2009;23:199-209
   PubMed Web of Science ®Google Scholar
• Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998;30:89-92,104
   PubMedGoogle Scholar
• Bitzer J. Hormone withdrawal-associated symptoms: overlooked and under-explored. Gynecol Endocrinol 2013;29:530-5
   PubMed Web of Science ®Google Scholar
• Loder EW, Buse DC, Golub JR. Headache and combination estrogen–progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache 2005;45:224-31
   PubMedGoogle Scholar
• Ekstrom P, Akerlund M, Forsling M, et al. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment – effect on uterine contractility. Br J Obstet Gynaecol 1992;99:680-4
   PubMedGoogle Scholar
• Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea. Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. Am J Med 1981;70:535-41
   PubMed Web of Science ®Google Scholar
• Wong CL, Farquhar C, Roberts H, et al. Oral contraceptive pill as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2009;4:CD002120
   Google Scholar
• Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev 2014;7:CD004695
   Google Scholar
• Guilbert E, Boroditsky R, Black A, et al. Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007. J Obstet Gynaecol Canada 2007;29:S1-32
   PubMedGoogle Scholar
• Willis SA, Kuehl TJ, Spiekerman AM, et al. Greater inhibition of the pituitary – ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 2006;74:100-3
   PubMed Web of Science ®Google Scholar
• Archer DF, Nakajima ST, Sawyer AT, et al. Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive. Obstet Gynecol 2013;122:601-7
   PubMed Web of Science ®Google Scholar
• Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary–ovarian axis suppression with three oral contraceptive regimens. Contraception 2008;77:162-70
   PubMed Web of Science ®Google Scholar
• Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004;70:359-63
   PubMed Web of Science ®Google Scholar
• den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999;59:357-62
   PubMed Web of Science ®Google Scholar
• Endrikat J, Gerlinger C, Plettig K, et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use. Gynecol Endocrinol 2003;17:107-14
   PubMed Web of Science ®Google Scholar
• Sulak PJ. Continuous oral contraception: changing times. Best Pract Res Clin Obstet Gynaecol 2008;22:355-74
   PubMed Web of Science ®Google Scholar
• Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception 2004;70:371-7
   PubMed Web of Science ®Google Scholar
• van Heusden AM, Fauser BC. Residual ovarian activity during oral steroid contraception. Hum Reprod Update 2002;8:345-58
   PubMed Web of Science ®Google Scholar
• van Heusden AM, Fauser BC. Activity of the pituitary–ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 1999;59:237-43
   PubMed Web of Science ®Google Scholar
• Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 1996;54:71-7
   PubMed Web of Science ®Google Scholar
• Sullivan H, Furniss H, Spona J, et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999;72:115-20
   PubMed Web of Science ®Google Scholar
• Potter L, Oakley D, de Leon-Wong E, et al. Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996;28:154-8
   PubMedGoogle Scholar
• Guilbert E, Black A, Dunn S, et al. Missed hormonal contraceptives: new recommendations. J Obstet Gynaecol Canada 2008;30:1050-62,63-77
   PubMedGoogle Scholar
• Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception 2008;78:16-25
   PubMed Web of Science ®Google Scholar
• Killick SR, Fitzgerald C, Davis A. Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol 1998;179:S18-24
   PubMed Web of Science ®Google Scholar
• Reape KZ, DiLiberti CE, Hendy CH, et al. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception 2008;77:34-9
   PubMed Web of Science ®Google Scholar
• Reid R, Leyland L, Wolfman W, et al. SOGC clinical practice guideline. No. 252, December 2010. Oral contraceptives and the risk of venous thromboembolism: an update. J Obstet Gynaecol Canada 2010;32:1192-204
   PubMedGoogle Scholar
• Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347:f5298
   PubMed Web of Science ®Google Scholar
• Rott H. Contraception, venous thrombosis and biological plausability. Minerva Medica 2013;104:161-7
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception 2014;89:253-63
   PubMed Web of Science ®Google Scholar
• Beaber EF, Buist DS, Barlow WE, et al. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 2014;74:4078-89
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32
   PubMed Web of Science ®Google Scholar
• Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 2013;88:678-83
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14
   PubMed Web of Science ®Google Scholar
• Gierisch JM, Coeytaux RR, Urrutia RP, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Canc Epidemiol Biomarkers Prev 2013;22:1931-43
   PubMed Web of Science ®Google Scholar